Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
305 artigos
Células T CD8+ GZMK+ promovem inflamação crônica e doenças relacionadas ao envelhecimento — uma ameaça imunológica recém-reconhecida que vai além da citotoxicidade.
Nova pesquisa revela que o efgartigimod reformula as populações de células B na miastenia gravis, induzindo células plasmáticas regulatórias associadas à melhora clínica.
Um ensaio clínico francês concluído investigou se anticorpos aberrantes que visam a grelina e o alfa-MSH perturbam a regulação do apetite em pacientes com transtornos alimentares.
Ensaio de fase 1 examina se o vesatolimod pode estimular com segurança a resposta imune em controladores de HIV durante a interrupção do tratamento.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
A meta-analysis of 19,000 children finds JIA patients are significantly more likely to develop thyroid autoimmunity, with clear screening targets identified.
A comprehensive JAMA review clarifies first-line treatments for acute and chronic low back pain, reshaping clinical practice.
Researchers tested whether eosinophil β1 integrin activation in blood could track disease activity, potentially sparing patients repeat invasive procedures.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
A major Lancet review reveals 27 million women suffer postpartum haemorrhage annually, costing $10.4B and claiming 43,000 lives — with most deaths preventable.
A Phase 1 pilot trial explores whether the IL-12/23 blocker ustekinumab is safe and can reduce systemic inflammation in Sjögren's patients.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
